Eupraxia reports Phase 1b/2a RESOLVE data showing EP-104GI cuts moderate-to-severe odynophagia in EoE patients to 25% at 52 weeks
EPRX•Safety and next readout
Safety remained supportive, with no treatment-emergent or procedure-related serious adverse events reported across more than 130 treated patients.
A key interim readout from the Phase 2b placebo-controlled portion of RESOLVE is expected in Q4.
RESOLVE trial symptom-response data
Eupraxia Pharmaceuticals released new symptom-response data from its ongoing Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis.
- The analysis showed sustained improvements in painful swallowing and difficulty swallowing, with more patients shifting to milder or no symptoms.
- Moderate-to-severe odynophagia was reduced to 25% at 52 weeks.
